お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
967841

新型コロナウイルス感染症 (COVID-19) 診断検査の世界市場 (2020年第3四半期-2021年第4四半期):製品タイプ・サンプルタイプ・技術・エンドユーザー・地域/国別の分析・競合環境の分析

Global COVID-19 Diagnostic Testing Market: Focus on Product Type, Sample Type, Technology, End User, Country Data (30 Countries), and Competitive Landscape - Analysis and Forecast, 3Q-2020-4Q-2021

出版日: | 発行: BIS Research Inc. | ページ情報: 英文 369 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=104.83円
新型コロナウイルス感染症 (COVID-19) 診断検査の世界市場 (2020年第3四半期-2021年第4四半期):製品タイプ・サンプルタイプ・技術・エンドユーザー・地域/国別の分析・競合環境の分析
出版日: 2020年10月20日
発行: BIS Research Inc.
ページ情報: 英文 369 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の新型コロナウイルス感染症 (COVID-19) 診断検査の市場規模は予測期間中23.50%のCQGR (四半期平均成長率) で推移し、2021年第4四半期には356億4000万米ドルの規模に成長すると予測されています。COVID-19の世界的な感染者数の増加、診断検査開発の促進、技術革新、外部資金の投入、有利な法規制シナリオなどの要因が同市場の成長を推進しています。

当レポートでは、世界の新型コロナウイルス感染症 (COVID-19) 診断検査の市場を調査し、市場の定義と概要、市場成長への各種影響因子の分析、法規制環境、製品・検体タイプ・技術・エンドユーザー・地域/主要国など各種区分別の内訳、競合環境、主要企業のプロファイルなどをまとめています。

エグゼクティブサマリー

第1章 製品の定義

第2章 調査範囲

第3章 調査手法

第4章 市場概要

第5章 産業考察

  • 概要
  • 法的要件・枠組み:米国
  • 法的要件・枠組み:欧州
  • 法的要件・枠組み:アジア太平洋

第6章 市場力学

  • 概要
  • 影響分析
  • 促進要因
  • 抑制要因

第7章 競合情勢

  • 主な戦略・展開
  • 市場シェア分析

第8章 市場分析・予測:製品別

  • 概要
  • キット・アッセイ
  • 機器

第9章 市場分析・予測:検体タイプ別

  • 鼻咽頭スワブ
  • 中咽頭スワブ
    • 血液検体
    • 尿検体
    • その他

第10章 市場分析・予測:技術別

  • PCR
  • 等温増幅
  • その他
    • 免疫学的検査
      • ラテラルフローイムノアッセイ(LFIA)
      • 酵素免疫測定法(EIA)

第11章 市場分析・予測:エンドユーザー別

  • 概要
  • 病院・ヘルスケアセンター
  • 診断センター・クリニック
  • 研究機関
  • その他

第12章 市場分析・予測:地域別

  • 概要
  • 北米
    • 米国
    • カナダ
    • その他
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • ロシア
    • オランダ
    • その他
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 台湾
    • 韓国
    • シンガポール
    • オーストラリア
    • バングラデシュ
    • パキスタン
    • インドネシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • ペルー
    • アルゼンチン
    • チリ
    • その他
  • 中東
    • サウジアラビア
    • イラン
    • アラブ首長国連邦(UAE)
    • その他
  • アフリカ
    • 南アフリカ
    • ジンバブエ
    • アルジェリア
    • その他
  • オセアニア・その他の地域

第13章 企業プロファイル

  • Abbott Laboratories
  • BGI Group
  • Becton, Dickinson and Company
  • BioMerieux SA
  • Bio-Rad Laboratories, Inc.
  • CENTOGENE Holding AG
  • Cellex Inc.
  • CTK Biotech
  • Danaher Corporation
  • DiaSorin S.p.A
  • F. Hoffmann-La Roche Ltd
  • Hologic, Inc.
  • GenMark Diagnostics
  • PerkinElmer Inc.
  • QIAGEN N.V.
  • Quidel Corporation
  • Luminex Corporation
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
図表

List of Figures

  • Figure 1: Global COVID-19 Cumulative Cases
  • Figure 2: Impact Analysis of Market Drivers and Market Challenges on the Global COVID-19 Diagnostic Testing Market
  • Figure 3: Global COVID-19 Diagnostic Testing Market (by Product), Value ($Million), 2Q2020-4Q2021
  • Figure 4: Global COVID-19 Diagnostic Testing Market (by Sample Type), Value ($Million), 2Q2020-4Q2021
  • Figure 5: Global COVID-19 Diagnostic Testing Market (by Technology), Value ($Million), 2Q2020-4Q2021
  • Figure 6: Global COVID-19 Diagnostic Testing Market (by End User), Value ($Million), 2Q2020-4Q2021
  • Figure 7: Global COVID-19 Diagnostic Testing Market (by Region), Value ($Million), 2Q2020-4Q2021
  • Figure 2.1: Global COVID-19 Diagnostic Testing Market Segmentation
  • Figure 3.1: Global COVID-19 Diagnostic Testing Market: Research Methodology
  • Figure 3.2: Primary Research Methodology
  • Figure 3.3: Bottom-Up Approach (Segment-Wise Analysis)
  • Figure 3.4: Top-Down Approach (Segment-Wise Analysis)
  • Figure 4.1: Implications of COVID-19 on the Healthcare Sector: Short- and Long-Term Analysis
  • Figure 4.2: Global COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020 and 4Q2021
  • Figure 5.1: Procedure for Obtaining Emergency Use Authorization (EUA)
  • Figure 5.2: Components Considered for Clinical Evidence as per the IVDR
  • Figure 5.3: Procedure for IVD Medical Device Registration in China
  • Figure 6.1: Number of COVID-19 Confirmed Cases, Globally
  • Figure 7.1: Share of Key Developments and Strategies, January 2020 - July 2020
  • Figure 7.2: Product Approval Share (by Company), January 2020 - July 2020
  • Figure 7.3: Synergistic Activities Share (by Company), January 2020 - July 2020
  • Figure 7.4: Product Launch and Upgradations Share (by Company), January 2020 - July 2020
  • Figure 7.6: Market Share Analysis for Global COVID-19 Diagnostic Testing Market, 2Q2020
  • Figure 8.1: Global COVID-19 Diagnostic Testing Market (by Product Type)
  • Figure 8.2: Global COVID-19 Diagnostic Testing Market (by Product Type), 2Q2020 and 4Q2021
  • Figure 8.3: Global COVID-19 Diagnostic Testing Market (for Kits and Assays), Value ($Million), 1Q2020-4Q2021
  • Figure 8.4: Global COVID-19 Diagnostic Testing Market (for Instruments), Value ($Million), 1Q2020-4Q2021
  • Figure 9.1: Global COVID-19 Diagnostic Testing Market (by Sample Type)
  • Figure 9.2: Global COVID-19 Diagnostic Testing Market (by Sample Type), 2Q2020-4Q2021
  • Figure 9.3: Global COVID-19 Diagnostic Testing Market (by Swab), 2Q2020 and 4Q2021
  • Figure 9.4: Global COVID-19 Diagnostic Testing Market (for Nasopharyngeal Swabs), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 9.5: Global COVID-19 Diagnostic Testing Market (for Nasopharyngeal Swabs), Value ($Million), 1Q2020-4Q2021
  • Figure 9.6: Global COVID-19 Diagnostic Testing Market (for Oropharyngeal Swabs), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 9.7: Global COVID-19 Diagnostic Testing Market (for Oropharyngeal Swabs), Value ($Million), 1Q2020-4Q2021
  • Figure 9.8: Global COVID-19 Diagnostic Testing Market (for Blood Samples), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 9.9: Global COVID-19 Diagnostic Testing Market (for Blood Samples), Value ($Million), 1Q2020-4Q2021
  • Figure 9.10: Global COVID-19 Diagnostic Testing Market (for Urine Samples), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 9.11: Global COVID-19 Diagnostic Testing Market (for Urine Samples), Value ($Million), 1Q2020-4Q2021
  • Figure 9.12: Global COVID-19 Diagnostic Testing Market (for Other Samples), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 9.13: Global COVID-19 Diagnostic Testing Market (for Other Samples), Value ($Million), 1Q2020-4Q2021
  • Figure 10.1: Global COVID-19 Diagnostic Testing Market (by Technology)
  • Figure 10.2: Global COVID-19 Diagnostic Testing Market (by Technology), 2Q2020-4Q2021
  • Figure 10.3: Global COVID-19 Diagnostic Testing Market (by Molecular Assays), 2Q2020 and 4Q2021
  • Figure 10.4: Global COVID-19 Diagnostic Testing Market (for PCR), Value ($Million), 1Q2020-4Q2021
  • Figure 10.5: Global COVID-19 Diagnostic Testing Market (for RT-PCR), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 10.6: Global COVID-19 Diagnostic Testing Market (for RT-PCR), Value ($Million), 1Q2020-4Q2021
  • Figure 10.7: Global COVID-19 Diagnostic Testing Market (for ddPCR), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 10.8: Global COVID-19 Diagnostic Testing Market (for ddPCR), Value ($Million), 1Q2020-4Q2021
  • Figure 10.9: Global COVID-19 Diagnostic Testing Market (for Isothermal Amplification), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 10.10: Global COVID-19 Diagnostic Testing Market (for Isothermal Amplification), Value ($Million), 1Q2020-4Q2021
  • Figure 10.11: Global COVID-19 Diagnostic Testing Market (for Others), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 10.12: Global COVID-19 Diagnostic Testing Market (for Others), Value ($Million), 1Q2020-4Q2021
  • Figure 10.13: Global COVID-19 Diagnostic Testing Market (by Immunoassays), 2Q2020 and 4Q2021
  • Figure 10.14: Global COVID-19 Diagnostic Testing Market (for Later Flow Immunoassay), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 10.15: Global COVID-19 Diagnostic Testing Market (for Later Flow Immunoassay), Value ($Million), 1Q2020-4Q2021
  • Figure 10.16: Global COVID-19 Diagnostic Testing Market (for Enzyme Immunoassay), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 10.17: Global COVID-19 Diagnostic Testing Market (for Enzyme Immunoassay), Value ($Million), 1Q2020-4Q2021
  • Figure 11.1: Global COVID-19 Diagnostic Testing Market (by End User)
  • Figure 11.2: Global COVID-19 Diagnostic Testing Market (by End User), 2Q2020-4Q2021
  • Figure 11.3: Global COVID-19 Diagnostic Testing Market (for Hospitals and Healthcare Centers), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 11.4: Global COVID-19 Diagnostic Testing Market (for Hospitals and Healthcare Centers), Value ($Million), 1Q2020-4Q2021
  • Figure 11.5: Global COVID-19 Diagnostic Testing Market (for Diagnostic Centers and Clinics), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 11.6: Global COVID-19 Diagnostic Testing Market (for Diagnostic Centers and Clinics), Value ($Million), 1Q 2020-4Q2021
  • Figure 11.7: Global COVID-19 Diagnostic Testing Market (for Research Institutions), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 11.8: Global COVID-19 Diagnostic Testing Market (for Research Institutions), Value ($Million), 1Q2020-4Q2021
  • Figure 11.9: Global COVID-19 Diagnostic Testing Market (for Other End Users), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 11.10: Global COVID-19 Diagnostic Testing Market (for Other End Users), Value ($Million), 1Q2020-4Q2021
  • Figure 12.1: Global COVID-19 Diagnostic Testing Market (by Region)
  • Figure 12.2: Global COVID-19 Diagnostic Testing Market (by Region), Value ($Million), 1Q2020-4Q2021
  • Figure 12.3: Global COVID-19 Diagnostic Testing Market (by Region), 1Q2020 and 4Q2021
  • Figure 12.4: North America COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
  • Figure 12.5: North America COVID-19 Diagnostic Testing Market (by Country), Value ($Million), 1Q2020-4Q2021
  • Figure 12.6: North America: Market Dynamics
  • Figure 12.7: U.S. COVID-19 Diagnostic Testing Market, Value (Million), 1Q2020-4Q2021
  • Figure 12.8: U.S. Month-Wise COVID-19 Cases, as of August 15, 2020
  • Figure 12.9: U.S. COVID-19 Diagnostic Testing Market (by Technology), 1Q2020-4Q2021
  • Figure 12.10: U.S. COVID-19 Diagnostic Testing Market (for Molecular Assays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.11: U.S. COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), Q12020-4Q2021
  • Figure 12.12: U.S. COVID-19 Diagnostic Testing Market (for Immunoassay), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.13: U.S. COVID-19 Diagnostic Testing Market (for Immunoassay), Value ($Million), 2020-2021
  • Figure 12.14: Canada COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
  • Figure 12.15: Canada Month-Wise COVID-19 Cases, as of August 15, 2020
  • Figure 12.16: Canada COVID-19 Diagnostic Testing Market (by Technology), 1Q2020-4Q2021
  • Figure 12.17: Canada COVID-19 Diagnostic Testing Market (for Molecular Assays, Volume (Thousand Units), Q12020-4Q2021
  • Figure 12.18: Canada COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.19: Canada COVID-19 Diagnostic Testing Market (for Immunoassays), Volume (Thousand Units), Q12020-Q42021
  • Figure 12.20: Canada COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.21: Rest-of-North America COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
  • Figure 12.22: Rest-of-North America COVID-19 Diagnostic Testing Market (by Technology), Value ($Million), 1Q2020-4Q2021
  • Figure 12.23: Rest-of-North America COVID-19 Diagnostic Testing Market (for Molecular Assays, Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.24: Rest-of-North America COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), Q12020-4Q2021
  • Figure 12.25: Rest-of-North America COVID-19 Diagnostic Testing Market (for Immunoassays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.26: Rest-of-North America COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.27: Europe COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
  • Figure 12.28: Europe: Market Dynamics
  • Figure 12.29: Europe COVID-19 Diagnostic Testing Market (by Country), Value ($Million), 1Q2020-4Q2021
  • Figure 12.30: Germany COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
  • Figure 12.31: Germany Month-Wise COVID-19 Cases, as of August 15, 2020
  • Figure 12.32: Germany COVID-19 Diagnostic Testing Market (by Technology), Value ($Million), 1Q2020-4Q2021
  • Figure 12.33: Germany COVID-19 Diagnostic Testing Market (for Molecular Assays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.34: Germany COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.35: Germany COVID-19 Diagnostic Testing Market (for Immunoassays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.36: Germany COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.37: U.K. COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
  • Figure 12.38: U.K. Month-Wise COVID-19 Cases, as of August 15, 2020
  • Figure 12.39: U.K. COVID-19 Diagnostic Testing Market (by Technology), Value ($Million), 1Q2020-4Q2021
  • Figure 12.40: U.K. COVID-19 Diagnostic Testing Market (for Molecular Assays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.41: U.K. COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.42: U.K. COVID-19 Diagnostic Testing Market (for Immunoassays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.43: U.K. COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.44: France COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
  • Figure 12.45: France Month-Wise COVID-19 Cases, as of August 15, 2020
  • Figure 12.46: France COVID-19 Diagnostic Testing Market (by Technology), Value ($Million) 1Q2020-4Q2021
  • Figure 12.47: France COVID-19 Diagnostic Testing Market (for Molecular Assays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.48: France COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.49: France COVID-19 Diagnostic Testing Market (for Immunoassays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.50: France COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.51: Italy COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
  • Figure 12.52: Italy Month-Wise COVID-19 Cases, as of August 15, 2020
  • Figure 12.53: Italy COVID-19 Diagnostic Testing Market (by Technology), Value ($Million), 1Q2020-4Q2021
  • Figure 12.54: Italy COVID-19 Diagnostic Testing Market (for Molecular Assays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.55: Italy COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.56: Italy COVID-19 Diagnostic Testing Market (for Immunoassay), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.57: Italy COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.58: Spain COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
  • Figure 12.59: Spain Month-Wise COVID-19 Cases, as of August 15, 2020
  • Figure 12.60: Spain COVID-19 Diagnostic Testing Market (by Technology), Value ($Million), 1Q2020-4Q2021
  • Figure 12.61: Spain COVID-19 Diagnostic Testing Market (for Molecular Assays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.62: Spain COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.63: Spain COVID-19 Diagnostic Testing Market (for Immunoassays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.64: Spain COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.65: Russia COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
  • Figure 12.66: Russia Month-Wise COVID-19 Cases, as of August 15, 2020
  • Figure 12.67: Russia COVID-19 Diagnostic Testing Market (by Technology), Value ($Million), 1Q2020-4Q2021
  • Figure 12.68: Russia COVID-19 Diagnostic Testing Market (for Molecular Assays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.69: Russia COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.70: Russia COVID-19 Diagnostic Testing Market (for Immunoassays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.71: Russia COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.72: Netherlands COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
  • Figure 12.73: Netherlands Month-Wise COVID-19 Cases, as of August 15, 2020
  • Figure 12.74: Netherlands COVID-19 Diagnostic Testing Market (by Technology), Value ($Million), 1Q2020-4Q2021
  • Figure 12.75: Netherlands COVID-19 Diagnostic Testing Market (for Molecular Assays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.76: Netherlands COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.77: Netherlands COVID-19 Diagnostic Testing Market (for Immunoassays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.78: Netherlands COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.79: Rest-of-Europe COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
  • Figure 12.80: Rest-of-Europe COVID-19 Diagnostic Testing Market (by Technology), Value ($Million), 1Q2020-4Q2021
  • Figure 12.81: Rest-of-Europe COVID-19 Diagnostic Testing Market (for Molecular Assays, Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.82: Rest-of-Europe COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), Q12020-4Q2021
  • Figure 12.83: Rest-of-Europe COVID-19 Diagnostic Testing Market (for Immunoassays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.84: Rest-of-Europe COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.85: Asia-Pacific COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
  • Figure 12.86: APAC: Market Dynamics
  • Figure 12.87: APAC COVID-19 Diagnostic Testing Market (by Country), Value ($Million), 1Q2020-4Q2021
  • Figure 12.88: China COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
  • Figure 12.89: China Month-Wise COVID-19 Cases, as of August 15, 2020
  • Figure 12.90: China COVID-19 Diagnostic Testing Market (by Technology), Value ($Million), 1Q2020-4Q2021
  • Figure 12.91: The China COVID-19 Diagnostic Testing Market (for Molecular Assays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.92: The China COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.93: China COVID-19 Diagnostic Testing Market (for Immunoassays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.94: China COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.95: India COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
  • Figure 12.96: India Month-Wise COVID-19 Cases, as of August 15, 2020
  • Figure 12.97: India COVID-19 Diagnostic Testing Market (by Technology), Value ($Million), 1Q2020-4Q2021
  • Figure 12.98: India COVID-19 Diagnostic Testing Market (for Molecular Assays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.99: India COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.100: India COVID-19 Diagnostic Testing Market (for Immunoassays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.101: India COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.102: Japan COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
  • Figure 12.103: Japan Month-Wise COVID-19 Cases, as of August 15, 2020
  • Figure 12.104: Japan COVID-19 Diagnostic Testing Market (by Technology), Value ($Million), 1Q2020-4Q2021
  • Figure 12.105: Japan COVID-19 Diagnostic Testing Market (for Molecular Assays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.106: Japan COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.107: Japan COVID-19 Diagnostic Testing Market (for Immunoassays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.108: Japan COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.109: Taiwan COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
  • Figure 12.110: Taiwan Month-Wise COVID-19 Cases, as of August 15, 2020
  • Figure 12.111: Taiwan COVID-19 Diagnostic Testing Market (by Technology), Value ($Million), 1Q2020-4Q2021
  • Figure 12.112: Taiwan COVID-19 Diagnostic Testing Market (for Molecular Assays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.113: Taiwan COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.114: Taiwan COVID-19 Diagnostic Testing Market (for Immunoassays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.115: Taiwan COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.116: South Korea COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
  • Figure 12.117: South Korea Month-Wise COVID-19 Cases, as of August 15, 2020
  • Figure 12.118: South Korea COVID-19 Diagnostic Testing Market (by Technology), Value ($Million), 1Q2020-4Q2021
  • Figure 12.119: South Korea COVID-19 Diagnostic Testing Market (for Molecular Assays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.120: South Korea COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.121: South Korea COVID-19 Diagnostic Testing Market (for Immunoassays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.122: South Korea COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.123: Singapore COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
  • Figure 12.124: Singapore Month-Wise COVID-19 Cases, as of August 15, 2020
  • Figure 12.125: Singapore COVID-19 Diagnostic Testing Market (by Technology), Value ($Million), 1Q2020-4Q2021
  • Figure 12.126: Singapore COVID-19 Diagnostic Testing Market (for Molecular Assays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.127: Singapore COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.128: Singapore COVID-19 Diagnostic Testing Market (for Immunoassays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.129: Singapore COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.130: Australia COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
  • Figure 12.131: Australia Month-Wise COVID-19 Cases, as of August 15, 2020
  • Figure 12.132: Australia COVID-19 Diagnostic Testing Market (by Technology), Value ($Million), 1Q2020-4Q2021
  • Figure 12.133: Australia COVID-19 Diagnostic Testing Market (for Molecular Assays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.134: Australia COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.135: Australia COVID-19 Diagnostic Testing Market (for Immunoassays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.136: Australia COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.137: Bangladesh COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
  • Figure 12.138: Bangladesh Month-Wise COVID-19 Cases, as of August 15, 2020
  • Figure 12.139: Bangladesh COVID-19 Diagnostic Testing Market (by Technology), Value ($Million), 1Q2020-4Q2021
  • Figure 12.140: Bangladesh COVID-19 Diagnostic Testing Market (for Molecular Assays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.141: Bangladesh COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.142: Bangladesh COVID-19 Diagnostic Testing Market (for Immunoassays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.143: Bangladesh COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.144: Pakistan COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
  • Figure 12.145: Pakistan Month-Wise COVID-19 Cases, as of August 15, 2020
  • Figure 12.146: Pakistan COVID-19 Diagnostic Testing Market (by Technology), Value ($Million), 1Q2020-4Q2021
  • Figure 12.147: Pakistan COVID-19 Diagnostic Testing Market (for Molecular Assays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.148: Pakistan COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.149: Pakistan COVID-19 Diagnostic Testing Market (for Immunoassays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.150: Pakistan COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.151: Indonesia COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
  • Figure 12.152: Indonesia Month-Wise COVID-19 Cases, as of August 15, 2020
  • Figure 12.153: Indonesia COVID-19 Diagnostic Testing Market (by Technology), Value ($Million), 1Q2020-4Q2021
  • Figure 12.154: Indonesia COVID-19 Diagnostic Testing Market (for Molecular Assays), Volume, 1Q2020-4Q2021
  • Figure 12.155: Indonesia COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.156: Indonesia COVID-19 Diagnostic Testing Market (for Immunoassays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.157: Indonesia COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.158: RoAPAC COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
  • Figure 12.159: Rest-of-APAC COVID-19 Diagnostic Testing Market (by Technology), Value ($Million), 1Q2020-4Q2021
  • Figure 12.160: Rest-of-APAC COVID-19 Diagnostic Testing Market (for Molecular Assays, Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.161: Rest-of-APAC COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), Q12020-4Q2021
  • Figure 12.162: Rest-of-APAC COVID-19 Diagnostic Testing Market (for Immunoassays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.163: Rest-of-APAC COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.164: Latin America COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
  • Figure 12.165: Latin America: Market Dynamics
  • Figure 12.166: Latin America COVID-19 Diagnostic Testing Market (by Country), Value ($Million), 1Q2020-4Q2021
  • Figure 12.167: Brazil COVID-19 Diagnostic Testing Market, Value ($Million), 3Q2020-4Q2021
  • Figure 12.168: Brazil Month-Wise COVID-19 Cases, as of August 15, 2020
  • Figure 12.169: Brazil COVID-19 Diagnostic Testing Market (by Technology), Value ($Million), 1Q2020-4Q2021
  • Figure 12.170: Brazil COVID-19 Diagnostic Testing Market (for Molecular Assays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.171: Brazil COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.172: Brazil COVID-19 Diagnostic Testing Market (for Immunoassays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.173: Brazil COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.174: Mexico COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
  • Figure 12.175: Mexico Month-Wise COVID-19 Cases, as of August 15, 2020
  • Figure 12.176: Mexico COVID-19 Diagnostic Testing Market (by Technology), Value ($Million), 1Q2020-4Q2021
  • Figure 12.177: Mexico COVID-19 Diagnostic Testing Market (for Molecular Assays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.178: Mexico COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.179: Mexico COVID-19 Diagnostic Testing Market (for Immunoassays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.180: Mexico COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.181: Peru COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
  • Figure 12.182: Peru Month-Wise COVID-19 Cases, as of August 15, 2020
  • Figure 12.183: Peru COVID-19 Diagnostic Testing Market (by Technology), Value ($Million), 1Q2020-4Q2021
  • Figure 12.184: Peru COVID-19 Diagnostic Testing Market (for Molecular Assays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.185: Peru COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.186: Peru COVID-19 Diagnostic Testing Market (for Immunoassays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.187: Peru COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.188: Argentina COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
  • Figure 12.189: Argentina Month-Wise COVID-19 Cases, as of August 15, 2020
  • Figure 12.190: Argentina COVID-19 Diagnostic Testing Market (by Technology), Value ($Million), 1Q2020-4Q2021
  • Figure 12.191: Argentina COVID-19 Diagnostic Testing Market (for Molecular Assays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.192: Argentina COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.193: Argentina COVID-19 Diagnostic Testing Market (for Immunoassays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.194: Argentina COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.195: Chile COVID-19 Diagnostic Testing Market, $Million, Q12020-Q42021
  • Figure 12.196: Chile Month-Wise COVID-19 Cases, as of August 15, 2020
  • Figure 12.197: Chile COVID-19 Diagnostic Testing Market (by Technology), Value ($Million), 1Q2020-4Q2021
  • Figure 12.198: Chile COVID-19 Diagnostic Testing Market (for Molecular Assays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.199: Chile COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.200: Chile COVID-19 Diagnostic Testing Market (for Immunoassays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.201: Chile COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.202: RoLA COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
  • Figure 12.203: Rest-of-Latin America COVID-19 Diagnostic Testing Market (by Technology), Value ($Million), 1Q2020-4Q2021
  • Figure 12.204: Rest-of-Latin America COVID-19 Diagnostic Testing Market (for Molecular Assays, Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.205: Rest-of-Latin America COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), Q12020-4Q2021
  • Figure 12.206: Rest-of-Latin America COVID-19 Diagnostic Testing Market (for Immunoassays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.207: Rest-of-Latin America COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.208: Middle East COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
  • Figure 12.209: Middle East: Market Dynamics
  • Figure 12.210: Middle East COVID-19 Diagnostic Testing Market (by Country), Value ($Million), 1Q2020-4Q2021
  • Figure 12.211: KSA COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
  • Figure 12.212: KSA Month-Wise COVID-19 Cases, as of August 15, 2020
  • Figure 12.213: KSA COVID-19 Diagnostic Testing Market (by Technology), Value ($Million), 1Q2020-4Q2021
  • Figure 12.214: KSA COVID-19 Diagnostic Testing Market (for Molecular Assays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.215: KSA COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.216: KSA COVID-19 Diagnostic Testing Market (for Immunoassays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.217: KSA COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.218: Iran COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
  • Figure 12.219: Iran Month-Wise COVID-19 Cases, as of August 15, 2020
  • Figure 12.220: Iran COVID-19 Diagnostic Testing Market (by Technology), Value ($Million), 1Q2020-4Q2021
  • Figure 12.221: Iran COVID-19 Diagnostic Testing Market (for Molecular Assays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.222: Iran COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.223: Iran COVID-19 Diagnostic Testing Market (for Immunoassays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.224: Iran COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.225: U.A.E. COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
  • Figure 12.226: U.A.E. Month-Wise COVID-19 Cases, as of August 15, 2020
  • Figure 12.227: U.A.E. COVID-19 Diagnostic Testing Market (by Technology), Value ($Million), 1Q2020-4Q2021
  • Figure 12.228: U.A.E. COVID-19 Diagnostic Testing Market (for Molecular Assays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.229: U.A.E. COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.230: U.A.E. COVID-19 Diagnostic Testing Market (for Immunoassays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.231: U.A.E. COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.232: Rest-of-Middle East COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
  • Figure 12.233: Rest-of-Middle East COVID-19 Diagnostic Testing Market (by Technology), Value ($Million), 1Q2020-4Q2021
  • Figure 12.234: Rest-of-Middle East COVID-19 Diagnostic Testing Market (for Molecular Assays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.235: Rest-of-Middle East COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.236: Rest-of-Middle East COVID-19 Diagnostic Testing Market (for Immunoassays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.237: Rest-of-Middle East COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.238: Africa COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
  • Figure 12.239: Africa: Market Dynamics
  • Figure 12.240: Africa COVID-19 Diagnostic Testing Market (by Country), Value ($Million), 1Q2020-4Q2021
  • Figure 12.241: South Africa COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
  • Figure 12.242: South Africa Month-Wise COVID-19 Cases, as of August 15, 2020
  • Figure 12.243: South Africa COVID-19 Diagnostic Testing Market (by Technology), Value ($Million), 1Q2020-4Q2021
  • Figure 12.244: South Africa COVID-19 Diagnostic Testing Market (for Molecular Assays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.245: South Africa COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.246: South Africa COVID-19 Diagnostic Testing Market (for Immunoassays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.247: South Africa COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.248: Zimbabwe COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
  • Figure 12.249: Zimbabwe Month-Wise COVID-19 Cases, as of August 15, 2020
  • Figure 12.250: Zimbabwe COVID-19 Diagnostic Testing Market (by Technology), Value ($Million), 1Q2020-4Q2021
  • Figure 12.251: Zimbabwe COVID-19 Diagnostic Testing Market (for Molecular Assays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.252: Zimbabwe COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.253: Zimbabwe COVID-19 Diagnostic Testing Market (for Immunoassays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.254: Zimbabwe COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.255: Algeria COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
  • Figure 12.256: Algeria Month-Wise COVID-19 Cases, as of August 15, 2020
  • Figure 12.257: Algeria COVID-19 Diagnostic Testing Market (by Technology), Value ($Million), 1Q2020-4Q2021
  • Figure 12.258: Algeria COVID-19 Diagnostic Testing Market (by Molecular Assays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.259: Algeria COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.260: Algeria COVID-19 Diagnostic Testing Market (for Immunoassays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.261: Algeria COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.262: Rest-of-Africa COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
  • Figure 12.263: Rest-of-Africa COVID-19 Diagnostic Testing Market (by Technology), Value ($Million), 1Q2020-4Q2021
  • Figure 12.264: Rest-of-Africa COVID-19 Diagnostic Testing Market (for Molecular Assays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.265: Rest-of-Africa COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.266: Rest-of-Africa COVID-19 Diagnostic Testing Market (for Immunoassays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.267: Rest-of-Africa COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.268: Oceania/RoW COVID-19 Diagnostic Testing Market, Value ($Million), 1Q2020-4Q2021
  • Figure 12.269: Oceania/RoW COVID-19 Diagnostic Testing Market (by Technology), Value ($Million), 1Q2020-4Q2021
  • Figure 12.270: Oceania/RoW COVID-19 Diagnostic Testing Market (for Molecular Assays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.271: Oceania/RoW COVID-19 Diagnostic Testing Market (for Molecular Assays), Value ($Million), 1Q2020-4Q2021
  • Figure 12.272: Oceania/RoW COVID-19 Diagnostic Testing Market (for Immunoassays), Volume (Thousand Units), 1Q2020-4Q2021
  • Figure 12.273: Oceania/RoW COVID-19 Diagnostic Testing Market (for Immunoassays), Value ($Million), 1Q2020-4Q2021
  • Figure 13.1: Total Number of Companies Profiled
  • Figure 13.2: Competitive Benchmarking of Abbott Laboratories
  • Figure 13.3: Competitive Benchmarking of BGI Group
  • Figure 13.4: Competitive Benchmarking of Becton, Dickinson and Company
  • Figure 13.5: Competitive Benchmarking of BioMerieux SA
  • Figure 13.6: Competitive Benchmarking of Bio-Rad Laboratories, Inc.
  • Figure 13.7: Competitive Benchmarking of CENTOGENE Holding AG
  • Figure 13.8: Competitive Benchmarking of Cellex Inc.
  • Figure 13.9: Competitive Benchmarking of CTK Biotech
  • Figure 13.10: Competitive Benchmarking of Danaher Corporation
  • Figure 13.11: Competitive Benchmarking of DiaSorin S.p.A
  • Figure 13.12: Competitive Benchmarking of F. Hoffmann-La Roche Ltd
  • Figure 13.13: Competitive Benchmarking of Hologic, Inc.
  • Figure 13.14: Competitive Benchmarking of GenMark Diagnostics
  • Figure 13.15: Competitive Benchmarking of PerkinElmer Inc.
  • Figure 13.16: Competitive Benchmarking of QIAGEN N.V.
  • Figure 13.17: Competitive Benchmarking of Quidel Corporation
  • Figure 13.18: Competitive Benchmarking of Luminex Corporation
  • Figure 13.19: Competitive Benchmarking of Siemens Healthineers AG
  • Figure 13.20: Competitive Benchmarking of Thermo Fisher Scientific Inc.

List of Tables

  • Table 5.1: Registration Criteria for IVD Medical Devices as per the NMPA
  • Table 6.1: Impact Analysis of Market Drivers
  • Table 6.2: Impact Analysis of Market Restraints
  • Table 12.1: Key Players Offering Molecular Assays in the U.S.
  • Table 12.2: Key Players Offering Immunoassays in the U.S.
  • Table 12.3: Key Players Offering Molecular Assays in Canada
  • Table 12.4: Key Players Offering Immunoassays in Canada
  • Table 12.5: Key Players Offering Molecular Assays in Germany
  • Table 12.6: Key Players Offering Immunoassays in Germany
  • Table 12.7: Key Players Offering Molecular Assays in the U.K.
  • Table 12.8: Key Players Offering Immunoassays in the U.K.
  • Table 12.9: Key Players Offering Molecular Assays in France
  • Table 12.10: Key Players Offering Molecular Assays in France
  • Table 12.11: Key Players Offering Molecular Assays in Italy
  • Table 12.12: Key Players Offering Immunoassays in Italy
  • Table 12.13: Key Players Offering Molecular Assays in Spain
  • Table 12.14: Key Players Offering Immunoassays in Spain
  • Table 12.15: Key Players Offering Molecular Assays in Netherlands
  • Table 12.17: Key Players Offering Molecular Assays in China
  • Table 12.18: Key Players Offering Immunoassays in China
  • Table 12.19: Key Players Offering Molecular Assays in India
  • Table 12.20: Key Players Offering Immunoassays in India
  • Table 12.21: Key Players Offering Molecular Assays in Japan
  • Table 12.22: Key Players Offering Immunoassays in Japan
  • Table 12.23: Key Players Offering Molecular Assays in Taiwan
  • Table 12.24: Key Players Offering Molecular Assays in South Korea
  • Table 12.25: Key Players Offering Immunoassays in South Korea
  • Table 12.26: Key Players Offering Molecular Assays in Singapore
  • Table 12.27: Key Players Offering Immunoassays in Singapore
  • Table 12.28: Key Players Offering Molecular Assays in Australia
  • Table 12.29: Key Players Offering Immunoassays in Australia
目次
Product Code: BHP0959SA

"Global COVID-19 Diagnostic Testing Market to Reach $35.64 Billion by 4Q2021."

Market Report Coverage - COVID-19 Diagnostic Testing

Market Segmentation

  • Product - Kits and Assays, and Instruments
  • Sample Type - Swabs, Blood Samples, Urine Samples, and Other Samples
  • Technology - Molecular Assays and Immunoassays
  • End User - Hospitals and Healthcare Centers, Diagnostic Centers and Clinics, Research Institutions, and Other End Users

Regional Segmentation

  • North America - U.S., Canada, and Rest-of-North America
  • Europe - Germany, U.K., France, Italy, Spain, Russia, Netherlands and Rest-of-Europe
  • Asia-Pacific - China, India, Japan, Taiwan, South Korea, Singapore, Australia, Bangladesh, Pakistan, Indonesia, and Rest-of-Asia-Pacific
  • Latin America - Brazil, Mexico, Peru, Argentina, Chile, and Rest-of-Latin America
  • Middle East - Kingdom of Saudi Arabia (KSA), Iran, United Arab Emirates (UAE), and Rest-of-Middle East
  • Africa - South Africa, Zimbabwe, Algeria, and Rest-of-Africa
  • Oceania/Rest-of-the-World

Growth Drivers

  • Rising Cases of COVID-19 Globally, Inciting the Development of Diagnostic Tests
  • Technological Innovation Resulting in Market Pull
  • Significant External Funding Supporting Market Growth
  • Favourable Regulatory Scenario Aiding Companies to Launch COVID-19 Diagnostic Testing Products

Market Challenges

  • Less Efficiency of Rapid COVID-19 Diagnostic Testing as Compared with that of Laboratory Testing
  • Shortage of Skilled Professionals and Trained Lab-Technicians
  • Shortage of COVID-19 Diagnostic Test Reagents
  • Significant Dampening of the Market due to the Expected Launch of COVID-19 Vaccine

Market Opportunities

  • Massive Scope for Adoption of COVID-19 Point-of-Care (POC) Testing Products in Emerging Nations

Key Companies Profiled

Abbott Laboratories, BGI Group, Becton, Dickinson and Company, bioMerieux SA, Bio-Rad Laboratories, Inc., CENTOGENE Holding AG, Cellex Inc., CTK Biotech, Danaher Corporation, DiaSorin S.p.A, F. Hoffmann-La Roche Ltd, Hologic Inc., GenMark Diagnostics, PerkinElmer Inc., QIAGEN N.V., Luminex Corporation, Siemens Healthineers AG, and Thermo Fisher Scientific Inc.

Key Questions Answered in this Report:

  • What are the major market drivers, challenges, and opportunities in the global COVID-19 diagnostic testing market?
  • What are the underlying structures resulting in the emerging trends within the global COVID-19 diagnostic testing market?
  • How the COVID-19 pandemic impacted the global healthcare system?
  • What are the key development strategies which are being implemented by the major players in order to sustain in the competitive market?
  • What are the key regulatory implications in developed and developing regions for COVID-19 diagnostic testing?
  • What is the reimbursement scenario for the global COVID-19 diagnostic testing market?
  • How each segment of the market is expected to grow during the forecast period from 3Q2020 to 4Q2021 and what is the anticipated revenue to be generated by each of the segments on the basis of:
    • Product Type (Kits and Assays, and Instruments)
    • Sample Type (Swabs, Blood Samples, Urine Samples, and Others)
    • Technology (Molecular Assays, and Immunoassays)
    • End User (Hospitals and Healthcare Centers, Diagnostic Centers and Clinics, Research Institutions, and Others)
    • Region, including North America, Europe, Asia-Pacific, Latin America, Middle East, Africa, and Oceania/Rest-of-the-World
  • Who are the leading players with significant offerings to the global COVID-19 diagnostic testing market? What is the expected market dominance for each of these leading players?
  • Which companies are anticipated to be highly disruptive in the future and why?
  • What are the major strategies adopted by the countries for COVID-19 diagnostic testing?
  • What are the current unmet needs that are being faced?

Market Overview

Our healthcare experts have found COVID-19 Diagnostic Testing industry to be one of the most rapidly evolving and dynamic markets and the global market for COVID-19 diagnostic testing is predicted to grow at a CQGR of 23.50% over the forecast period of 3Q2020-4Q2021. The market is driven by certain factors, which include rising cases of COVID-19 globally, inciting the development of diagnostic tests, technological innovation resulting in market pull, significant external funding supporting market growth, and favourable regulatory scenario aiding companies to launch COVID-19 diagnostic testing products.

The market is favoured by the developments in the field of COVID-19 diagnostic testing solutions, particularly kits and assays, which are being developed by the emerging and the legacy diagnostic companies worldwide. Currently, the COVID-19 diagnostic testing industry is witnessing upsurge on account of growing number of cases worldwide coupled with the massive issuance of emergency use authorizations (EUAs) from the regulatory bodies to the manufacturers.

Furthermore, several diagnostic companies are focusing on the development of point-of-care (POC) rapid COVID-19 diagnostics tests having higher sensitivity and low turn-around time to benefit the patients, further providing provisions for the healthcare professions to offer treatment modalities.

Within the research report, the market is segmented on the basis of product type, sample type, technology, end users, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.

Competitive Landscape

The exponential rise in the number of COVID-19 cases on the global level has created a buzz among the diagnostic companies to invest in the development of efficient and rapid diagnostic testing solutions. Due to the diverse product and pipeline portfolio and intense market penetration, Abbott Laboratories has been a pioneer in this field and been a significant competitor in this market.

Several other companies such as Danaher Corporation, PerkinElmer Inc., and F. Hoffmann-La Roche Ltd, have also launched their respective COVID-19 diagnostic testing products, such as Xpert Xpress SARS-CoV-2, PerkinElmer SARS-CoV-2 Real-time RT-PCR Assay, and Cobas SARS-CoV-2 Test respectively, to compete with Abbott's market dominance.

On the basis of region, Asia-Pacific (APAC) holds the largest share of the COVID-19 diagnostic testing market and is anticipated to grow at the fastest CQGR during the forecast period, 3Q2020-4Q2021. Growing number of COVID-19 cases, growing emphasis in the development of novel diagnostic technologies, and rising healthcare awareness, among others, are some of the factors attributable to its largest share in the market.

Table of Contents

Executive Summary

1 Product Definition

  • 1.1 Inclusion and Exclusion

2 Research Scope

  • 2.1 Scope of the Study
  • 2.2 Key Questions Answered in the Report

3 Research Methodology

  • 3.1 COVID-19 Diagnostic Testing: Research Methodology
  • 3.2 Data Sources
    • 3.2.1 Primary Data Sources
    • 3.2.2 Secondary Data Sources
  • 3.3 Market Estimation Model

4 Market Overview

  • 4.1 Market Definition
  • 4.2 Impact of COVID-19 on Human Health
  • 4.3 Implications of COVID-19 on the Healthcare Sector
  • 4.4 Market Footprint and Growth Potential, Value ($Million), 2020-2021

5 Industry Insights

  • 5.1 Overview
  • 5.2 Legal Requirements and Framework in the U.S.
    • 5.2.1 Emergency Use Authorization (EUA)
  • 5.3 Legal Requirements and Framework in Europe
  • 5.4 Legal Requirement and Framework in the Asia-Pacific Region
    • 5.4.1 China
    • 5.4.2 Japan

6 Market Dynamics

  • 6.1 Overview
  • 6.2 Impact Analysis
  • 6.3 Drivers
    • 6.3.1 Rising Cases of COVID-19 Globally, Inciting the Development of Diagnostic Tests
    • 6.3.2 Technological Innovation Resulting in Market Pull
    • 6.3.3 Significant External Funding Supporting Market Growth
    • 6.3.4 Favorable Regulatory Scenario Aiding Companies to Launch COVID-19 Diagnostic Testing Products
  • 6.4 Restraints
    • 6.4.1 Less Efficient Rapid COVID-19 Diagnostic Testing as Compared to Laboratory Testing
    • 6.4.2 Shortage of Skilled Professionals and Trained Lab-Technicians
    • 6.4.3 Shortage of COVID-19 Diagnostic Test Reagents
    • 6.4.4 Significant Dampening of the Market Due to the Expected Launch of COVID-19 Vaccine
    • 6.4.5 Massive Scope for Adoption of COVID-19 Point-of-Care (POC) Testing Products in Emerging Nations

7 Competitive Landscape

  • 7.1 Key Strategies and Developments
    • 7.1.1 Product Approvals
    • 7.1.2 Synergistic Activities
    • 7.1.3 Product Launch and Upgradations
    • 7.1.4 Business Expansion and Funding
  • 7.2 Market Share Analysis

8 Global COVID-19 Diagnostic Testing Market (by Product)

  • 8.1 Overview
  • 8.2 Kits and Assays
  • 8.3 Instruments

9 Global COVID-19 Diagnostic Testing Market (by Sample Type)

  • 9.1 Overview
  • 9.2 Swabs
    • 9.2.1 Nasopharyngeal Swabs
    • 9.2.2 Oropharyngeal Swabs
  • 9.3 Blood Samples
  • 9.4 Urine Samples
  • 9.5 Other Samples

10 Global COVID-19 Diagnostic Testing Market (by Technology)

  • 10.1 Overview
  • 10.2 Molecular Assays
    • 10.2.1 Polymerase Chain Reaction (PCR)
      • 10.2.1.1 Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR)
      • 10.2.1.2 Droplet Digital Polymerase Chain Reaction (ddPCR)
    • 10.2.2 Isothermal Amplification
    • 10.2.3 Others
  • 10.3 Immunoassays
    • 10.3.1 Lateral Flow Immunoassay (LFIA)
    • 10.3.2 Enzyme Immunoassay (EIA)

11 Global COVID-19 Diagnostic Testing Market (by End User)

  • 11.1 Overview
  • 11.2 Hospitals and Healthcare Centers
  • 11.3 Diagnostic Centers and Clinics
  • 11.4 Research Institutions
  • 11.5 Other End Users

12 Global COVID-19 Diagnostic Testing Market (by Region)

  • 12.1 Overview
  • 12.2 North America
    • 12.2.1 U.S.
      • 12.2.1.1 Strategies Adopted by the U.S. for COVID-19 Diagnostic Testing
      • 12.2.1.2 U.S. COVID-19 Diagnostic Testing Market (by Technology)
        • 12.2.1.2.1 Molecular Assays
        • 12.2.1.2.2 Immunoassay
    • 12.2.2 Canada
      • 12.2.2.1 Strategies Adopted by Canada for COVID-19 Diagnostic Testing
      • 12.2.2.2 Canada COVID-19 Diagnostic Testing Market (by Technology)
        • 12.2.2.2.1 Molecular Assays
        • 12.2.2.2.2 Immunoassays
    • 12.2.3 Rest-of-North America
      • 12.2.3.1 Rest-of-North America COVID-19 Diagnostic Testing Market (by Technology)
        • 12.2.3.1.1 Molecular Assays
        • 12.2.3.1.2 Immunoassays
  • 12.3 Europe
    • 12.3.1 Germany
      • 12.3.1.1 Strategies Adopted by Germany for COVID-19 Diagnostic Testing
      • 12.3.1.2 Germany COVID-19 Diagnostic Testing Market (by Technology)
        • 12.3.1.2.1 Molecular Assays
        • 12.3.1.2.2 Immunoassays
    • 12.3.2 U.K.
      • 12.3.2.1 Strategies Adopted by the U.K. for COVID-19 Diagnostic Testing
      • 12.3.2.2 U.K. COVID-19 Diagnostic Testing Market (by Technology)
        • 12.3.2.2.1 Molecular Assays
        • 12.3.2.2.2 Immunoassays
    • 12.3.3 France
      • 12.3.3.1 Strategies Adopted by France for COVID-19 Diagnostic Testing
      • 12.3.3.2 France COVID-19 Diagnostic Testing Market (by Technology)
        • 12.3.3.2.1 Molecular Assays
        • 12.3.3.2.2 Immunoassays
    • 12.3.4 Italy
      • 12.3.4.1 Strategies Adopted by Italy for COVID-19 Diagnostic Testing
      • 12.3.4.2 Italy COVID-19 Diagnostic Testing Market (by Technology)
        • 12.3.4.2.1 Molecular Assays
        • 12.3.4.2.2 Immunoassays
    • 12.3.5 Spain
      • 12.3.5.1 Strategies Adopted by Spain for COVID-19 Diagnostic Testing
      • 12.3.5.2 Spain COVID-19 Diagnostic Testing Market (by Technology)
        • 12.3.5.2.1 Molecular Assays
        • 12.3.5.2.2 Immunoassays
    • 12.3.6 Russia
      • 12.3.6.1 Russia COVID-19 Diagnostic Testing Market (by Technology)
        • 12.3.6.1.1 Molecular Assays
        • 12.3.6.1.2 Immunoassays
    • 12.3.7 Netherlands
      • 12.3.7.1 Strategies Adopted by Netherlands for COVID-19 Diagnostic Testing
      • 12.3.7.2 Netherlands COVID-19 Diagnostic Testing Market (by Technology)
        • 12.3.7.2.1 Molecular Assays
        • 12.3.7.2.2 Immunoassays
    • 12.3.8 Rest-of-Europe
      • 12.3.8.1 Rest-of-Europe COVID-19 Diagnostic Testing Market (by Technology)
        • 12.3.8.1.1 Molecular Assays
        • 12.3.8.1.2 Immunoassays
  • 12.4 Asia-Pacific
    • 12.4.1 China
      • 12.4.1.1 Strategies Adopted by China for COVID-19 Diagnostic Testing
      • 12.4.1.2 China COVID-19 Diagnostic Testing Market (by Technology)
        • 12.4.1.2.1 Molecular Assays
        • 12.4.1.2.2 Immunoassays
    • 12.4.2 India
      • 12.4.2.1 Strategies Adopted by India for COVID-19 Diagnostic Testing
      • 12.4.2.2 India COVID-19 Diagnostic Testing Market (by Technology)
        • 12.4.2.2.1 Molecular Assays
        • 12.4.2.2.2 Immunoassays
    • 12.4.3 Japan
      • 12.4.3.1 Strategies Adopted by Japan for COVID-19 Diagnostic Testing
      • 12.4.3.2 Japan COVID-19 Diagnostic Testing Market (by Technology)
        • 12.4.3.2.1 Molecular Assays
        • 12.4.3.2.2 Immunoassays
    • 12.4.4 Taiwan
      • 12.4.4.1 Strategies Adopted by Taiwan for COVID-19 Diagnostic Testing
      • 12.4.4.2 Taiwan COVID-19 Diagnostic Testing Market (by Technology)
        • 12.4.4.2.1 Molecular Assays
        • 12.4.4.2.2 Immunoassays
    • 12.4.5 South Korea
      • 12.4.5.1 Strategies Adopted by South Korea for COVID-19 Diagnostic Testing
      • 12.4.5.2 South Korea COVID-19 Diagnostic Testing Market (by Technology)
        • 12.4.5.2.1 Molecular Assays
        • 12.4.5.2.2 Immunoassays
    • 12.4.6 Singapore
      • 12.4.6.1 Strategies Adopted by Singapore for COVID-19 Diagnostic Testing
      • 12.4.6.2 Singapore COVID-19 Diagnostic Testing Market (by Technology)
        • 12.4.6.2.1 Molecular Assays
        • 12.4.6.2.2 Immunoassays
    • 12.4.7 Australia
      • 12.4.7.1 Strategies Adopted by Australia for COVID-19 Diagnostic Testing
      • 12.4.7.2 Australia COVID-19 Diagnostic Testing Market (by Technology)
        • 12.4.7.2.1 Molecular Assays
        • 12.4.7.2.2 Immunoassays
    • 12.4.8 Bangladesh
      • 12.4.8.1 Strategies Adopted by Bangladesh for COVID-19 Diagnostic Testing
      • 12.4.8.2 Bangladesh COVID-19 Diagnostic Testing Market (by Technology)
        • 12.4.8.2.1 Molecular Assays
        • 12.4.8.2.2 Immunoassays
    • 12.4.9 Pakistan
      • 12.4.9.1 Strategies Adopted by Pakistan for COVID-19 Diagnostic Testing
      • 12.4.9.2 Pakistan COVID-19 Diagnostic Testing Market (by Technology)
        • 12.4.9.2.1 Molecular Assays
        • 12.4.9.2.2 Immunoassays
    • 12.4.10 Indonesia
      • 12.4.10.1 Strategies Adopted by Indonesia for COVID-19 Diagnostic Testing
      • 12.4.10.2 Indonesia COVID-19 Diagnostic Testing Market (by Technology)
        • 12.4.10.2.1 Molecular Assays
        • 12.4.10.2.2 Immunoassays
    • 12.4.11 Rest-of-APAC(RoAPAC)
      • 12.4.11.1 Rest-of-APAC COVID-19 Diagnostic Testing Market (by Technology)
        • 12.4.11.1.1 Molecular Assays
        • 12.4.11.1.2 Immunoassays
  • 12.5 Latin America
    • 12.5.1 Brazil
      • 12.5.1.1 Strategies Adopted by Brazil for COVID-19 Diagnostic Testing
      • 12.5.1.2 Brazil COVID-19 Diagnostic Testing Market (by Technology)
        • 12.5.1.2.1 Molecular Assays
        • 12.5.1.2.2 Immunoassays
    • 12.5.2 Mexico
      • 12.5.2.1 Strategies Adopted by Mexico for COVID-19 Diagnostic Testing
      • 12.5.2.2 Mexico COVID-19 Diagnostic Testing Market (by Technology)
        • 12.5.2.2.1 Molecular Assays
        • 12.5.2.2.2 Immunoassays
    • 12.5.3 Peru
      • 12.5.3.1 Strategies Adopted by Peru for COVID-19 Diagnostic Testing
      • 12.5.3.2 Peru COVID-19 Diagnostic Testing Market (by Technology)
        • 12.5.3.2.1 Molecular Assays
        • 12.5.3.2.2 Immunoassays
    • 12.5.4 Argentina
      • 12.5.4.1 Strategies Adopted by Argentina for COVID-19 Diagnostic Testing
      • 12.5.4.2 Argentina COVID-19 Diagnostic Testing Market (by Technology)
        • 12.5.4.2.1 Molecular Assays
        • 12.5.4.2.2 Immunoassays
    • 12.5.5 Chile
      • 12.5.5.1 Strategies Adopted by Chile for COVID-19 Diagnostic Testing
      • 12.5.5.2 Chile COVID-19 Diagnostic Testing Market (by Technology)
        • 12.5.5.2.1 Molecular Assays
        • 12.5.5.2.2 Immunoassays
    • 12.5.6 Rest-of-Latin America (RoLA)
      • 12.5.6.1 Rest-of-Latin America COVID-19 Diagnostic Testing Market (by Technology)
        • 12.5.6.1.1 Molecular Assays
        • 12.5.6.1.2 Immunoassays
  • 12.6 Middle East
    • 12.6.1 Kingdom of Saudi Arabia
      • 12.6.1.1 Strategies Adopted by KSA for COVID-19 Diagnostic Testing
      • 12.6.1.2 KSA COVID-19 Diagnostic Testing Market (by Technology)
        • 12.6.1.2.1 Molecular Assays
        • 12.6.1.2.2 Immunoassays
    • 12.6.2 Iran
      • 12.6.2.1 Strategies Adopted by Iran for COVID-19 Diagnostic Testing
      • 12.6.2.2 Iran COVID-19 Diagnostic Testing Market (by Technology)
        • 12.6.2.2.1 Molecular Assays
        • 12.6.2.2.2 Immunoassays
    • 12.6.3 United Arab Emirates (U.A.E.)
      • 12.6.3.1 U.A.E. COVID-19 Diagnostic Testing Market (by Technology)
        • 12.6.3.1.1 Molecular Assays
        • 12.6.3.1.2 Immunoassays
    • 12.6.4 Rest-of-Middle East
      • 12.6.4.1 Rest-of-Middle East COVID-19 Diagnostic Testing Market (by Technology)
        • 12.6.4.1.1 Molecular Assays
        • 12.6.4.1.2 Immunoassays
  • 12.7 Africa
    • 12.7.1 South Africa
      • 12.7.1.1 Strategies Adopted by South Africa for COVID-19 Diagnostic Testing
      • 12.7.1.2 South Africa COVID-19 Diagnostic Testing Market (by Technology)
        • 12.7.1.2.1 Molecular Assays
        • 12.7.1.2.2 Immunoassays
    • 12.7.2 Zimbabwe
      • 12.7.2.1 Zimbabwe COVID-19 Diagnostic Testing Market (by Technology)
        • 12.7.2.1.1 Molecular Assays
        • 12.7.2.1.2 Immunoassays
    • 12.7.3 Algeria
      • 12.7.3.1 Algeria COVID-19 Diagnostic Testing Market (by Technology)
        • 12.7.3.1.1 Molecular Assays
        • 12.7.3.1.2 Immunoassays
    • 12.7.4 Rest-of-Africa
      • 12.7.4.1 Rest-of-Africa COVID-19 Diagnostic Testing Market (by Technology)
        • 12.7.4.1.1 Molecular Assays
        • 12.7.4.1.2 Immunoassays
  • 12.8 Oceania/Rest-of-the-World
    • 12.8.1 Oceania/RoW COVID-19 Diagnostic Testing Market (by Technology)
    • 12.8.2 Molecular Assays
    • 12.8.3 Immunoassays

13 Company Profiles

  • 13.1 Overview
  • 13.2 Abbott Laboratories
    • 13.2.1 Company Overview
    • 13.2.2 BIS Insights
  • 13.3 BGI Group
    • 13.3.1 Company Overview
    • 13.3.2 BIS Insights
  • 13.4 Becton, Dickinson and Company
    • 13.4.1 Company Overview
    • 13.4.2 BIS Insights
  • 13.5 BioMerieux SA
    • 13.5.1 Company Overview
    • 13.5.2 BIS Insights
  • 13.6 Bio-Rad Laboratories, Inc.
    • 13.6.1 Company Overview
    • 13.6.2 BIS Insights
  • 13.7 CENTOGENE Holding AG
    • 13.7.1 Company Overview
    • 13.7.2 BIS Insights
  • 13.8 Cellex Inc.
    • 13.8.1 Company Overview
    • 13.8.2 BIS Insights
  • 13.9 CTK Biotech
    • 13.9.1 Company Overview
    • 13.9.2 BIS Insights
  • 13.1 Danaher Corporation
    • 13.10.1 Company Overview
    • 13.10.2 BIS Insights
  • 13.11 DiaSorin S.p.A
    • 13.11.1 Company Overview
    • 13.11.2 BIS Insights
  • 13.12 F. Hoffmann-La Roche Ltd
    • 13.12.1 Company Overview
    • 13.12.2 BIS Insights
  • 13.13 Hologic, Inc.
    • 13.13.1 Company Overview
    • 13.13.2 BIS Insights
  • 13.14 GenMark Diagnostics
    • 13.14.1 Company Overview
    • 13.14.2 BIS Insights
  • 13.15 PerkinElmer Inc.
    • 13.15.1 Company Overview
    • 13.15.2 BIS Insights
  • 13.16 QIAGEN N.V.
    • 13.16.1 Company Overview
    • 13.16.2 BIS Insights
  • 13.17 Quidel Corporation
    • 13.17.1 Company Overview
    • 13.17.2 BIS Insights
  • 13.18 Luminex Corporation
    • 13.18.1 Company Overview
    • 13.18.2 BIS Insights
  • 13.19 Siemens Healthineers AG
    • 13.19.1 Company Overview
    • 13.19.2 BIS Insights
  • 13.2 Thermo Fisher Scientific Inc.
    • 13.20.1 Company Overview
    • 13.20.2 BIS Insights
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.